Cargando…
An evaluation of continuous subcutaneous infusions across seven NHS acute hospitals: is there potential for 48-hour infusions?
BACKGROUND: Continuous subcutaneous infusions (CSCIs) are commonly used in the United Kingdom as a way of administering medication to patients requiring symptom control when the oral route is compromised. These infusions are typically administered over 24 h due to currently available safety data. Th...
Autores principales: | Baker, J., Dickman, A., Mason, S., Bickerstaff, M., Jackson, R., McArdle, A., Lawrence, I., Stephenson, F., Paton, N., Kirk, J., Waters, B., Ellershaw, J. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7341565/ https://www.ncbi.nlm.nih.gov/pubmed/32635902 http://dx.doi.org/10.1186/s12904-020-00611-3 |
Ejemplares similares
-
The current evidence base for the feasibility of 48-hour continuous subcutaneous infusions (CSCIs): A systematically-structured review
por: Baker, James, et al.
Publicado: (2018) -
Identification of drug combinations administered by continuous subcutaneous infusion that require analysis for compatibility and stability
por: Dickman, Andrew, et al.
Publicado: (2017) -
Effectiveness of COVID-19 Convalescent Plasma Infusion Within 48 Hours of Hospitalization With SARS-CoV-2 Infection
por: Lattanzio, Natalia, et al.
Publicado: (2021) -
On the Subcutaneous Injection of Blood, Infusion (Subcutaneous) and Intravenous Transfusion
por: Oehler,, et al.
Publicado: (1888) -
Continuous subcutaneous insulin infusion: practical issues
por: Saboo, Banshi D., et al.
Publicado: (2012)